StockData
GLAUKOS Corp logo

GLAUKOS Corp (GKOS) company profile

GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 7/30215% above fair value
$243.25−1.63 (-0.67%)

Close on Nov 17, 2026Market cap $14.40BP/E –Yield –

About Glaukos

Surgical & Medical Instruments & Apparatus, SIC 3841

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio and pipeline include micro-invasive glaucoma surgery devices such as iStent, iStent inject W, and iStent infinite, sustained-release pharmaceuticals including iDose TR, and corneal health treatments such as Photrexa and Epioxa. The company operates in key therapeutic areas centered on glaucoma and corneal health, serving ophthalmic surgeons and specialized eye care professionals.

The company conducts business domestically within the United States and across international markets, with operations and regulatory activities spanning countries such as the United Kingdom, Germany, France, and Japan. Glaukos operates facilities in locations including Burlington, Massachusetts, and Aliso Viejo, California, with its principal executive offices and global headquarters situated in Aliso Viejo, California.

Summary of the business section of Glaukos's latest annual report, written by StockData.

Company profile

Company

Legal name
GLAUKOS Corp
Headquarters
Aliso Viejo, CA
Address
1 Glaukos Way 92656
Phone
(949) 367-9600
Employees
1,094, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Irvine, California

Stock & identifiers

Ticker
GKOS
Exchange
NYSE
IPO date
Jun 25, 2015
Shares outstanding
59M, Oct 26, 2026
Public float
$5.91B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1192448
CUSIP
377322102
ISIN
US3773221029
FIGI
BBG000WG2LQ1
Share class FIGI
BBG001T91NX8
LEI
5299004JA1LHE21M6T14
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Thomas William BurnsCHAIRMAN & CEO, Director1,768,667
Joseph E. GilliamPRESIDENT & COO71,602
Tomas NavratilCHIEF DEVELOPMENT OFFICER37,328
Alex R. ThurmanSVP & CHIEF FINANCIAL OFFICER63,906
Gilbert H. KlimanDirector42,608
Aimee S. WeisnerDirector49,688
Leana WenDirector21,092
Denice TorresDirector24,212
David F. HoffmeisterDirector87,725
Marc StapleyDirector39,327
Mark J. FoleyDirector60,267

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$12.03M$9.99M$4.71M$150$78
FY2024$9.03M$25.16M$3.13M$199$78
FY2023$8.65M$22.35M$3.04M$106$76
FY2022$6.27M$5.46M$2.93M$58$78
FY2021$7.26M-$172.51K$2.20M$59$106
FY2020$6.02M$11.77M$2.16M$138$131

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Thomas W. Burns
Chairman and Chief Executive Officer
$850.00K$7.65M$3.53M–$6.64K$12.03M+33%
Joseph E. Gilliam
President and Chief Operating Officer
$584.85K$6.50M–$689.01K$11.75K$7.79M+87%
Alex R. Thurman
Senior Vice President and Chief Financial Officer
$486.20K$2.44M––$15.75K$2.94M+20%
Tomas Navratil
Senior Vice President and Chief Development Officer
$499.40K$2.40M–$504.29K$11.75K$3.42M+23%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 25, 2015
Offer price
$18.00
Securities offered
6,000,000
Gross proceeds
$108.00M
Exchange
NYSE
First trading day
Jun 25, 2015
First-day close
$31.22+73.4%
Lock-up ends (est.)
Dec 22, 2015

“The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 1,094 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?